A Meta-analysis Of Everolimus-eluting Stents Versus Sirolimus-eluting Stents In The Treatment Of Coronary Artery Disease

Objective: To systematically evaluate the efficacy and safety ofeverolimus-eluting stents(EES) versus sirolimus-eluting stents (SES) inpatients with coronary artery disease undergoing percutaneous coronaryintervention.Method: The primary databases were searched to collect all therandomized controlled trials (RCTs) on EES versus SES in patients withcoronary artery disease from2000to2012. After the data extraction andmethodological quality evaluation, meta-analysis was conducted withReview manager5.0software.Results: A total of10randomized controlled trials were included.Among12937patients involved,6378were in the EES group, while theother6559were in the SES group. The results of meta-analysis showed thatEES was superior to SES in definite stent thrombosis[OR=0.47,95%CI(0.26,0.85), P=0.01]. In contrast, there were no significantdifferences between EES and SES in the target-lesionrevascularization[OR=0.85,95%CI(0.70,1.03), P=0.11], the target-vessel revascularization [OR=0.92,95%CI(0.77,1.09), P=0.33], cardiacdeath[OR=0.91,95%CI(0.69,1.20), P=0.52], major adverse cardiacevents[OR=0.89,95%CI(0.78,1.02), P=0.09], recurrence of myocardialinfarction[OR=0.95,95%CI (0.75,1.19), P=0.63].Conclusion：EES is more effective than SES in reducing the rate ofdefinite stent thrombosis.